By TrustedAINews Editorial Team | October 2026
A woman mentions a mole to her family doctor, almost in passing, at a checkup she booked for something else. A paramedic kneels beside a collapsed man and has minutes to decide which hospital gets him. A mother reaches through the walls of an incubator toward a newborn she has barely held.
None of these moments are rare. And most of what decides them is not medical knowledge. We know how to catch skin cancer, treat strokes, and clear newborn jaundice.
What decides them is timing and distance: whether the right tool is in the exam room, in the ambulance, or in a mother’s arms.
That is the thread running through this list. In this industry, claims are cheap. Proof is not.
So we held the phrase changing healthcare to a real standard: a cleared device, a published study, or patients already treated. The ten companies below each close one specific gap between a patient and care that should already be within reach. DermaSensor leads the list for moving specialist-level skin cancer detection into primary care.
Actuvi follows at number two for proving that remote monitoring improves pain outcomes at scale.
1. Actuvi
The entire software and technology layer for digital care, in the clinic’s own ecosystem.
Care is leaving the clinic. Remote and hybrid care have gone from experiment to expectation, and patients now assume their care team can follow them between visits. Where the patient expects continuity, the industry has offered scale: big telehealth networks and third-party contract clinicians who take the patient somewhere else.
The visit happens, but the care gets fragmented. The person on the screen does not know the patient. The data does not come back.
The clinic that actually owns the relationship watches from the outside. It is care that is there for the sake of being there.
Actuvi, an award-winning Remote Therapeutic Monitoring (RTM) platform, took the humbler route. Rather than stepping between clinics and their patients, Actuvi keeps everything inside the clinic’s own care ecosystem: the care team, the patients, and the data stay with the clinic or hospital running the musculoskeletal, pain management, respiratory, or behavioral health program.
Actuvi gives them the tools to do it, the entire software and technology layer: digital assessments, symptom tracking, alerts, dashboards, and billing support, all built around the clinic’s own care pathways. The belief underneath is simple.
Care happens best when it is delivered by local providers, the clinicians who know their patients best, even when that care is delivered digitally. Not by sending the patient somewhere new. Not by making them jump through hoops.
Humility means little without outcomes. Actuvi’s are published. In a published outcomes study the company conducted with Arizona Pain, a multi-specialty pain clinic, 831 patients completed 51,265 assessments over 15 months.
72% of patients reached meaningful pain improvement, the median time to response was 10 days, and medication compliance reached 91%. The most engaged patients were 5.2 times more likely to reach the clinically important improvement threshold than the least engaged. Every clinic that launches RTM with Actuvi gets a fully built program: Actuvi configures the assessments, sets clinical thresholds, trains the admin, clinical, and billing staff, and provides ongoing support.
It tracks all qualifying staff time and data transmission days, then generates billing reports with the correct CPT codes, supporting up to $180 per patient per month in revenue. The care team does not manually log hours.
2. DermaSensor
Skin cancer detection at the first appointment a patient already has.
Skin cancer is the most common cancer in the United States, and survival comes down to timing. The problem is that most suspicious moles are first seen not by a dermatologist. They are seen by a primary care physician, where the decision to refer or biopsy is a visual judgment call made in a few minutes.
Months can pass before a specialist confirms what that first appointment could have settled.
DermaSensor built a handheld device for exactly that moment. It shines light beneath the surface of a lesion and reads how the light scatters back from cellular structures, a technique called elastic scattering spectroscopy. A machine learning algorithm returns a risk result in seconds, covering melanoma, basal cell carcinoma, and squamous cell carcinoma, while the patient is still in the room.
The evidence has kept pace with the idea. The device received FDA De Novo clearance in 2024 after a pivotal study showed 96% sensitivity, and the company reports a 52% reduction in missed skin cancers when physicians use it.
More than 50,000 suspicious lesions have been scanned since launch, an estimated 7,500 of them cancers, according to the company. A $16 million Series B in October 2025 is funding the push into more primary care offices.
3. Forest Devices
Moving stroke triage into the ambulance.
Stroke treatment has to start within hours, and every minute of delay destroys brain tissue. Yet the people who reach the patient first, ambulance crews, have had no reliable way to tell whether a patient is having a stroke, or which kind, before choosing a hospital. The most time-sensitive decision in stroke care has been made with the least information.
Forest Devices, a Pittsburgh company founded by a former EMT, built its answer for the roadside rather than the lab. Its SignalNED system uses a rapidly deployable sensor cap to record the patient’s EEG, and a portable device analyzes the brain’s electrical activity and returns a readout of the patient’s neurologic state in five to seven minutes, fast enough to guide the transport decision while it still matters.
The underlying AlphaStroke technology earned FDA Breakthrough Device Designation in 2021. SignalNED received its first FDA 510(k) clearance in September 2024, with a second clearance following in 2025.
4. Qvin
The first and only FDA-cleared diagnostic menstrual pad.
More than 70% of medical decisions depend on blood work. And yet routine testing is easy to postpone, because it asks for a needle, an appointment, and a lab visit. So the conditions best caught early, from diabetes to thyroid disorders, are often the ones caught late.
Qvin’s insight was that for half the population, the body already provides a monthly blood sample. The Q-Pad captures it during ordinary use through an embedded collection strip. The user mails it to a certified laboratory, and results return through an app.
No needle, no appointment, no new routine.
Don’t mistake it for a wellness gadget. The science is published in Clinical Chemistry: menstrual blood mirrors venous blood for key biomarkers, with correlations of 0.96 for HbA1c and above 0.9 for thyroid and ovarian reserve hormones. FDA clearance currently covers A1c testing, and the company is extending the same approach toward conditions like endometriosis.
5. Unlimited Tomorrow
A custom bionic arm for around $8,000.
A multi-articulating bionic arm can cost tens of thousands of dollars. Insurance often declines to cover one. Children outgrow prosthetics as they grow.
The result is a quiet population of people, many of them kids, who simply go without.
Easton LaChappelle started building robotic hands as a teenager and founded Unlimited Tomorrow in 2014. The company’s TrueLimb arm is 3D printed to the user’s own limb scan, matched to their skin tone from hundreds of options, controlled by muscle signals, and weighs just 1.1 pounds.
Scanning, fitting, and delivery all happen remotely, with no prosthetist visit. That is part of how a custom device lands at around $8,000.
TrueLimb users now range from children to adults, and the company has donated arms to amputees affected by the war in Ukraine.
6. Osteoboost Health
A third option between medication and watchful waiting.
Osteopenia affects tens of millions of postmenopausal women in the United States. The standard path has offered two unsatisfying doors: drugs many patients cannot tolerate, or watchful waiting that ends, too often, in a fracture. Hip fractures in older adults remain one of the largest drivers of lost independence.
Osteoboost’s prescription device came out of an unlikely place: research originally developed to keep astronauts from losing bone in space. The belt is worn at the hips and delivers precisely calibrated vibration to the spine and hips, stimulating bone-building cells the way weight-bearing activity does.
Patients wear it for 30 minutes a day, while walking, cooking, or getting ready.
The FDA cleared it through the De Novo pathway in January 2024, the first drug-free prescription treatment for the condition. In a 12-month sham-controlled trial, women using it at least three times a week lost 85% less bone density in the spine and 55% less in the hip than the control group, with no device-related serious adverse events.
The company reports more than 2,500 prescribing physicians and raised $8 million in April 2026 to scale manufacturing and access.
7. Anodyne Nanotech
A patch for drugs that today only come as injections.
Ask someone on a GLP-1 what they dislike about it, and the answer is rarely the drug itself. It is the needle: the weekly routines patients abandon, the cold-chain shipping, the prices that keep these medicines out of reach for much of the world. That single fact drives most of what is hard about these drugs.
Anodyne Nanotech’s HeroPatch is a solid-state, porous microneedle patch that delivers multi-milligram doses of large-molecule drugs through the skin in dry form. It is stable at room temperature, its release profile can be tuned, and it turns a weekly injection into a patch worn briefly on the skin.
Anodyne is earlier stage than most companies on this list, and it earns its spot differently. Its lead program, ANN-101, is a once-weekly GLP-1 patch for obesity, and in preclinical work the patch delivered more GLP-1 than a standard semaglutide injection with no cold-chain requirement.
The Boston company closed a $12.6 million Series A in June 2026 to move ANN-101 into a Phase I clinical trial. It ranks here on the scale of what changes if the platform works: entire classes of injectable medicine delivered as patches.
8. Nanopath
Compressing a three-day diagnostic wait into 15 minutes.
Urinary tract infections are among the most common infections on earth, and women get the overwhelming majority of them. The diagnostic process has barely moved in decades: a culture takes days, so clinicians routinely prescribe antibiotics on a guess. Wrong guesses mean unresolved infections, repeat visits, and a steady contribution to antibiotic resistance.
Nanopath’s cartridge and reader system collapses that wait into a single office visit. From one urine sample, it identifies the pathogens causing a complicated UTI, along with key antibiotic resistance markers, in about 15 minutes.
The right antibiotic gets chosen in the same visit, not guessed three days early.
The FDA granted the platform Breakthrough Device Designation in November 2025, and the Cambridge, Massachusetts company develops its tests with clinical partners including Brigham and Women’s Hospital.
9. CorNeat Vision
An artificial cornea that needs no donor tissue.
In January 2021, a 78-year-old man who had been blind in both eyes for a decade read again and recognized his family members the day after surgery at Rabin Medical Center. He was the first patient to receive the CorNeat KPro, an artificial cornea.
Corneal disease blinds millions of people worldwide, and the standard cure, a transplant, depends entirely on donated corneal tissue. In most of the world, that tissue barely exists. Even where it does, rejection remains a risk.
The KPro is made from a proprietary synthetic material, EverMatrix, that mimics the eye’s own extracellular matrix. Rather than sitting on the eye the way earlier artificial corneas do, it integrates permanently with the tissue of the eye wall.
The European Innovation Council has backed the Ra’anana, Israel company with a 2.5 million euro grant, and the same material platform now underpins a glaucoma drainage device and a synthetic scleral patch in development.
10. Bilihome
Phototherapy the baby can wear.
Around 60% of newborns develop jaundice, and the company estimates a baby needs treatment for it every 2.3 seconds, roughly 14 million newborns a year. Standard phototherapy works. It also means days inside a hospital incubator under a lamp, eyes covered, separated from parents during the first days of bonding.
Bilihome began when co-founder Rick Wielens watched his own son treated in that isolation. The Dutch startup’s wearable phototherapy integrates hospital-grade blue light into a soft cotton romper, so the baby receives treatment while being held, fed, and comforted, at the bedside or at home.
The garment has been clinically evaluated with healthcare professionals.
Bilihome raised more than 2 million euros in 2025, including backing from Oost NL, to move from research into a commercial product.
Final Thoughts
None of these companies set out to change healthcare in the abstract. Each one found a specific place where the system fails patients, a gap of timing, distance, or access, and built a fix narrow enough to ship.
That is the standard we held this list to: a cleared device, a published study, or patients already treated. The companies that change healthcare are rarely the ones that say so. They are the ones that can prove it.
These ten are the ones we will keep tracking.
This article was independently researched and written by the TrustedAINews editorial team.
